Armistice Capital Acquires 4.99% Stake in Virax Biolabs Group

Armistice Capital, LLC and its managing member Steven Boyd have filed a Schedule 13G/A amendment reporting a 4.99% ownership stake in Virax Biolabs Group Limited (VRAX). The filing discloses ownership of 1,000,239 ordinary shares as of March 31, 2026, representing a new position for the investment firm. Armistice Capital serves as investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares, with Armistice Capital exercising voting and investment power over the securities. The filing indicates this is a passive investment not intended to influence control of the company. Both Armistice Capital and Steven Boyd share voting and dispositive power over the shares, with no sole power held by either party. The position falls just below the 5% threshold that would trigger additional reporting requirements.